期刊文献+

肝细胞性肝癌淋巴结转移的临床病理分析 被引量:2

Analysis of clinical pathologic characteristics of hepatocellular carcinoma with lymph nodes metastasis
下载PDF
导出
摘要 目的探讨原发性肝细胞性肝癌淋巴结转移的临床病理特点。方法对1998.1~2003.3经手术治疗的22例肝细胞性肝癌淋巴结转移的临床病例进行回顾性对照分析。结果临床表现、发病年龄、性别比、HBsAg阳性率、肿瘤大小、部位|合并肝硬化及肝功能与无淋巴结转移相比无差异(P>0.05);AFP≥400滋g/L阳性率为31.8%(7/22)、病理分化Ⅲ~Ⅳ级者占59.1%(13/22)和术后1年生存率13.6%(3/22),与无淋巴结转移相比存在显著性差异(P<0.05)。结论肝细胞性肝癌淋巴结转移有如下临床病理特点:(1)AFP≥400滋g/L的阳性率低。(2)原发肿瘤病理分化分级以Ⅲ~Ⅳ级多见。(3)小肝癌也存在淋巴结转移。(4)术后1年生存率低,提示淋巴结转移是影响预后的重要因素。(5)手术彻底清除转移淋巴结有可能提高生存率。 Objective To investigate the clinical pathologic characteristics of hepatocellular carcinoma with lymph nodes metastasis. Methods From January 1998 to March 2003, 22 cases with hepatocellular carcinoma associated with lymph node matastasis were analyzed retrospectively. Results The clinical manifestation,age, sex,AFP, HBsAg, associeted with liver cirrhosis,liver function and tumor diameter and position were not different.But the rate of AFP≥400 μg/L, Ⅲ-Ⅳ by pathological Edmondson-Steiner grade and survival rate of one year was 31.8% ,59.1% and 13.6% respectively.There were significant difference comparing with no lymph node metastasis (P 〈 0.05). Conclusion The clinical pathologic characteristics of hepatocellular carcinoma with lymph nodes metastasis are as follows: (1)The positive rate of AFP≥400 νg/L is low. (2)Pathological Edmondson- SteineⅢ~Ⅳ grade is more common.(3)lymph node metastasis may be found in the small HCC.(4) survival rate of one year is lower and lymph node metastasis is an important factor of influenced prognosis.(5)Surgical radical resection metastatic lymph node may improve survival rate.
出处 《岭南现代临床外科》 2005年第3期164-167,共4页 Lingnan Modern Clinics in Surgery
关键词 肝细胞性肝癌 淋巴结转移 病理特点 Hepatocellular carcinoma Lymph node metastasis Pathological characteristic
  • 相关文献

参考文献2

  • 1Takahiro Uenishi,Kazuhiro Hirohashi,Taichi Shuto,Shoji Kubo,Hiromu Tanaka,Chikaharu Sakata,Takashi Ikebe,Hiroaki Kinoshita. The Clinical Significance of Lymph Node Metastases in Patients Undergoing Surgery for Hepatocellular Carcinoma[J] 2000,Surgery Today(10):892~895
  • 2Yoshie Une,Kazuhito Misawa,Tsuyoshi Shimamura,Kazuhiro Ogasawara,Yoshihiro Masuko,Naoki Sato,Yasuaki Nakajima,Junichi Uchino. Treatment of lymph node recurrence in patients with hepatocellular carcinoma[J] 1994,Surgery Today(7):606~609

同被引文献8

  • 1李雁,汤钊猷,田波,钦伦秀,叶胜龙,孙瑞霞.细胞角质蛋白19与肝癌临床病理关系的探讨[J].中华肝脏病杂志,2004,12(6):341-343. 被引量:5
  • 2Omary MB, Ku NO, Toivola DM. Keratins.. guardians of the liver. Hepatology, 2002, 35 : 251-257.
  • 3Uenishi T, Kubo S, Hirohashi K, et al. Expression of bile duct-type cytokeratin in hepatocellular carcinoma in patients with hepatitis C virus and prior hepatitis B virus infection. Cancer Lett, 2002, 178: 107-112.
  • 4Micheal E, Hana A, Hua Q, et al. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone. Cancer Res, 1999, 59: 4111-4118.
  • 5Dobashi N, Fujita J, Murota M, et al. Binding of recombinant human cytokeratin 19 to lamintin: a possible role in interaction between intermediate filament derived from epithelial cells and extracellular matrixes. Cell Struct Funct, 2000, 25:171 175.
  • 6Ding SJ, Li Y, Tan YX, et al. From proteomic analysis to clinical significance: overexpression of cytokeratin 19 corre lares with hepatocellular carcinoma metastasis. Mol Cell Proteomics, 2004, 3: 73-81.
  • 7严律南,曾勇,文天夫,卢实春,李波,陈晓理,金立人.1038例原发性肝癌的外科治疗[J].中华外科杂志,2000,38(7):520-522. 被引量:26
  • 8ChaoYan Zheng-GangZhu Ying-YanYu JunJi YiZhang Yu-BaoJi MinYan JunChen Bing-YaLin.Expression of vascular endothelial growth factor C and chemokine receptor CCR7 in gastric carcinoma and their values in predicting lymph node metastasis[J].World Journal of Gastroenterology,2004,10(6):783-790. 被引量:54

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部